A-beta Aggregate Quantification via Fluorescent Probes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing Alzheimer's disease lack sensitivity and specificity in detecting and quantifying A-beta aggregates, particularly small, freely diffusing oligomers, leading to unreliable diagnosis and the absence of established biomarkers.
Innovation Solution
A method involving the immobilization of anti-A-beta antibodies on a substrate, followed by the application of fluorescent dye-labeled probes that specifically bind to A-beta aggregates, using spatially resolving fluorescence microscopy for detection, and employing internal or external standards to quantify aggregates, allowing for the characterization of size, composition, and number of A-beta aggregates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional diagnostic methods are used for Alzheimer's disease, then diagnosis can be performed, but sensitivity and specificity for detecting A-beta aggregates are insufficient
Solution Approach 1:
The detection method segments the diagnostic process into distinct steps: immobilization of scavenging molecules on substrate, application of sample, addition of fluorescent probes, and detection by spatially resolving fluorescence microscopy. This segmentation allows each step to be optimized independently, improving overall detection sensitivity for A-beta aggregates while maintaining diagnostic reliability
Solution Approach 2:
The invention changes the detection parameters by using spatially resolving fluorescence microscopy instead of conventional methods, and by employing fluorescently labeled probes that specifically bind to A-beta aggregates. This parameter change enables ultrasensitive detection with high specificity, directly addressing the insufficient sensitivity and reliability of conventional diagnostic methods
2Measurement precision
If current ELISA methods are used to detect A-beta oligomers, then quantification is possible, but antibodies recognize non-specific oligomers leading to inaccurate results
Solution Approach 1:
The invention introduces fluorescently labeled probes as intermediaries that specifically bind to A-beta aggregates. These probes act as mediators between the sample and detection system, providing specific recognition of A-beta oligomers while avoiding non-specific binding to other proteins. This intermediary approach eliminates the harmful non-specific recognition problem of conventional ELISA antibodies
Solution Approach 2:
The invention employs fluorescently labeled probes that produce color/fluorescence changes upon binding to A-beta aggregates. This optical signal change provides specific and accurate quantification of A-beta oligomers, eliminating the non-specific binding issues that plague conventional ELISA methods using standard antibodies
3Measurement precision
If PET radio tracers are used for imaging, then amyloid plaque deposition can be visualized, but costs are high and technical effort is required
Solution Approach 1:
The invention creates a simplified copy of the PET imaging concept by using fluorescently labeled probes instead of radioactive tracers. This copying approach maintains the ability to detect and quantify A-beta aggregates with high precision while eliminating the need for expensive radioactive materials and complex PET imaging infrastructure, making the technique more accessible
Solution Approach 2:
The invention substitutes the complex mechanical and technical system of PET radio tracers and imaging equipment with a simpler fluorescence-based detection system. By replacing radioactive labeling with fluorescent labeling and using standard fluorescence microscopy instead of PET scanners, the method achieves comparable plaque detection capability with significantly reduced technical complexity and cost
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method provides an ultrasensitive and selective means to detect and quantify A-beta aggregates, enabling accurate diagnosis and monitoring of Alzheimer's disease progression, with high sensitivity and specificity, and the potential for early detection and therapy assessment.
Implementation Method 1
immobilization of anti-A-beta antibodies on a substrate
Implementation Method 2
addition of probes marked for detection, which mark them by specific binding to ABeta aggregates and detection of the marked aggregates by means of spatially resolving fluorescence microscopy
Data Source
Figure 1~2
Figure 3A~4B
Figure 5A~6
AI summary
The invention relates to methods for selectively quantifying a-beta aggregates, comprising the immobilization of anti a-beta antibodies on a substrate, the application of the sample to be examined on the substrate, the addition of probes marked for detection, which mark said probes by specific binding to a-beta aggregates, and the detection of the marked aggregates.